Western Wealth Management LLC Increases Holdings in Amgen Inc. $AMGN

Western Wealth Management LLC lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 137.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,207 shares of the medical research company’s stock after purchasing an additional 5,910 shares during the quarter. Western Wealth Management LLC’s holdings in Amgen were worth $3,591,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. Norges Bank bought a new stake in shares of Amgen during the fourth quarter valued at about $2,164,162,000. Capital World Investors boosted its position in shares of Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after acquiring an additional 4,302,237 shares during the period. State Street Corp grew its stake in Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after acquiring an additional 1,287,310 shares in the last quarter. Geode Capital Management LLC increased its holdings in Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the period. Finally, Amundi lifted its stake in Amgen by 41.1% in the 4th quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock worth $1,111,854,000 after purchasing an additional 988,856 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AMGN. UBS Group boosted their price target on shares of Amgen from $400.00 to $420.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Piper Sandler restated an “overweight” rating on shares of Amgen in a research note on Friday, June 12th. Mizuho lifted their price target on Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research report on Tuesday, June 16th. Finally, Guggenheim boosted their price objective on Amgen from $340.00 to $343.00 and gave the stock a “neutral” rating in a report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Amgen currently has an average rating of “Hold” and a consensus target price of $357.00.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: The European Medicines Agency’s CHMP issued a positive opinion recommending broader use of Repatha to reduce cardiovascular risk in high-risk adults without a prior heart attack or stroke. The recommendation, based on Phase 3 data showing fewer major cardiovascular events, could expand Repatha’s addressable market in Europe. Amgen Wins Backing in Europe for Broader Repatha Use
• Positive Sentiment: Amgen declared a quarterly dividend of $2.52 per share, payable September 11 to shareholders of record on August 21. The ongoing payout, equivalent to $10.08 annually and an indicated yield of about 2.6%, supports the stock’s income appeal and signals continued confidence in cash generation. Amgen Announces 2026 Third Quarter Dividend
• Positive Sentiment: Amgen launched its first Amgen Scholars Program in India at IIIT Hyderabad. Although not a near-term financial driver, the initiative may strengthen the company’s research talent pipeline and scientific relationships. First Amgen Scholars Program in India Launches
• Neutral Sentiment: Wall Street’s attention is centered on second-quarter results. Amgen has a history of earnings beats, but investors will scrutinize product-sales trends, guidance and progress on MariTide, making the report a significant near-term catalyst. Amgen Q2 Earnings Preview
• Negative Sentiment: Barclays raised its price target to $360 but retained a Hold rating. With the target below the recent trading level, the update reinforces concerns that much of Amgen’s positive outlook may already be reflected in the shares. Barclays Boosts Amgen Price Target

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is owned by insiders.

Amgen Stock Down 0.6%

AMGN opened at $385.16 on Friday. The business’s fifty day simple moving average is $356.60 and its 200 day simple moving average is $353.77. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $398.00. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The stock has a market cap of $207.87 billion, a PE ratio of 26.80, a P/E/G ratio of 3.92 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same quarter in the previous year, the company posted $4.90 earnings per share. The company’s revenue was up 5.8% compared to the same quarter last year. As a group, research analysts expect that Amgen Inc. will post 22.31 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.6%. Amgen’s payout ratio is presently 70.15%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.